Vinva Investment Management Ltd Has $970,000 Position in Hologic, Inc. $HOLX

Vinva Investment Management Ltd lifted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 182.8% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 14,449 shares of the medical equipment provider’s stock after purchasing an additional 9,340 shares during the period. Vinva Investment Management Ltd’s holdings in Hologic were worth $970,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in HOLX. Winnow Wealth LLC acquired a new position in Hologic during the 3rd quarter worth about $26,000. Root Financial Partners LLC acquired a new stake in Hologic in the 3rd quarter valued at about $27,000. SJS Investment Consulting Inc. increased its position in Hologic by 341.5% in the 3rd quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock valued at $32,000 after acquiring an additional 362 shares in the last quarter. Loomis Sayles & Co. L P bought a new position in shares of Hologic in the second quarter worth about $33,000. Finally, Smartleaf Asset Management LLC raised its stake in shares of Hologic by 168.5% in the third quarter. Smartleaf Asset Management LLC now owns 494 shares of the medical equipment provider’s stock worth $33,000 after acquiring an additional 310 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

HOLX has been the subject of a number of research reports. Argus lowered shares of Hologic from a “buy” rating to a “hold” rating in a report on Monday, January 12th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hologic in a report on Wednesday, January 28th. Evercore lowered Hologic from an “outperform” rating to an “in-line” rating and decreased their price objective for the company from $79.00 to $78.00 in a research report on Monday, January 5th. Morgan Stanley lifted their target price on Hologic from $69.00 to $76.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 11th. Finally, BNP Paribas Exane downgraded Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 target price for the company. in a research report on Friday, November 21st. Two research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $78.42.

Hologic Trading Down 0.2%

Shares of NASDAQ HOLX opened at $75.59 on Tuesday. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $75.75. The firm has a market capitalization of $16.87 billion, a P/E ratio of 31.50, a P/E/G ratio of 2.25 and a beta of 0.73. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.04 and a quick ratio of 3.32. The company’s 50 day simple moving average is $75.06 and its 200 day simple moving average is $72.49.

Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 EPS for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). The business had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.07 billion. Hologic had a return on equity of 19.58% and a net margin of 13.18%.Hologic’s revenue was up 2.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.87 EPS. On average, analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.